e-Prescribe TRYNGOLZA through your electronic health record (EHR) system to:
OR
Download the TRYNGOLZA Start Form and fax the completed form to:
TRYNGOLZA can be prescribed using 1 of the 2 following options
OR
e-Prescribe TRYNGOLZA through your electronic health record (EHR) system to an in-network digital pharmacy (BlinkRx) or specialty pharmacy (Accredo, CVS Specialty, Optum Specialty Pharmacy)
OR
Download the TRYNGOLZA Start Form and fax the completed form to an in-network digital pharmacy (BlinkRx) or specialty pharmacy (Accredo, CVS Specialty, Optum Specialty Pharmacy)
TRYNGOLZA is available through a select pharmacy network
Confirm if use of a specific pharmacy below is required by your patient’s insurance plan or pharmacy benefit manager, as some have preferred pharmacies.
| Pharmacy | Phone | Fax |
|---|---|---|
| Accredo | Phone: 1-844-516-3319 | Fax: 1-888-302-1028 |
| BlinkRx | Phone: 1-844-926-2480 | Fax: 1-866-585-4631 |
| CVS Specialty | Phone: 1-800-237-2767 | Fax: 1-800-323-2445 |
| Optum Specialty Pharmacy | Phone: 1-855-427-4682 | Fax: 1-877-342-4596 |
Ionis Every Step™ is a support program designed to help your patients navigate treatment with TRYNGOLZA
Ionis Every Step offers a broad range of support for patients at every step of their treatment journey.
- Access support from our pharmacy partners
- Programs to support access and affordability for TRYNGOLZA, regardless of insurance type
- Support for starting and staying on TRYNGOLZA
- Educational resources to keep patients informed and engaged throughout their treatment journey
Help your patients take the next step with Ionis Every Step.
Encourage patients to enroll today by visiting TRYNGOLZA.com/Enroll, orif your patient needs additional support, they can call the Ionis Every Step TRYNGOLZA Support Center at 1-844-789-8744 (select option 2),Monday to Friday, 8 AM to 8 PM ET.
Important safety information & indication
CONTRAINDICATIONS
TRYNGOLZA® (olezarsen) is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.
Liver Enzyme Abnormalities
TRYNGOLZA can cause increases in liver enzymes and hepatic fat in adults. Increases in liver enzymes were more frequently reported with the 80 mg dose as compared with the 50 mg dose. Consider liver enzyme testing before TRYNGOLZA initiation and when clinically indicated thereafter. If persistent elevations in liver enzymes occur, consider dose interruption. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue TRYNGOLZA.
ADVERSE REACTIONS
Most common adverse reactions in patients with FCS (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.
Indication
TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Please see full Prescribing Information for TRYNGOLZA.
References: 1. TRYNGOLZA. Prescribing information. lonis Pharmaceuticals. 2. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al; Balance Investigators. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024,390(19):1781-1792. 3. Data on file. Human factors assessment. lonis Pharmaceuticals; 2024. 4. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-4806. 5. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. J Clin Lipidol. 2025;19(1):83-94. 6. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2021;78(9):960-993. 7. Javed F, Hegele RA, Garg A, et al. Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association. J Clin Lipidol. 2025;19(3):382-403. 8. Sanchez RJ, Ge W, Wei W, Ponda MP, Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20(1):72. 9. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):673-e691. 10. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(4):428-451. 11. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2020;105(12):3613-3682. 12. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. J Clin Lipidol. 2025;19(1)(online-only supplementary material):83-94. 13. D'Erasmo L, Di Costanzo A, Cassandra F, et al. Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes. Arterioscler Thromb Vasc Biol. 2019;39(12):2531-2541. 14. Saadatagah S, Larouche M, Naderian M, et al. Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2025;19(4):723-736. 15. Paquette M, Bernard S. The evolving story of multifactorial chylomicronemia syndrome. Front Cardiovasc Med. 2022;9:886266. 16. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-348. 17. Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898-907.e2. 18. Pallazola VA, Sajja A, Derenbecker R, et al. Prevalence of familial chylomicronemia syndrome in a quaternary care center. Eur J Prev Cardiol. 2020;27(19):2276-2278. 19. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an "FCS score". Atherosclerosis. 2018;275:265-272. 20. Brinton EA, Eckel RH, Gaudet D, et al. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025;403:119114. 21. Belhassen M, Van Ganse E, Nolin M, et al. 10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes. J Clin Endocrinol Metab. 2021;106(3):1332-e1342. 22. Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110(10):1497-1503. 23. Shemesh E, Zafrir B. Hypertriglyceridemia-related pancreatitis in patients with type 2 diabetes: links and risks. Diabetes Metab Syndr Obes. 2019;12:2041-2052. 24. Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30(2):80–85. 25. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200-2206. 26. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al; Balance Investigators. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19)(supplementary appendix):1781-1792. 27. Data on file. REF-01848. Ionis Pharmaceuticals; 2024. 28. Data on file. REF-01852. Ionis Pharmaceuticals; 2024. 29. Data on file. REF-01850. Ionis Pharmaceuticals; 2024.